Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers in the Department of Oncology have secured funding to characterise an insulin-like growth factor (IGF) signature for early detection and risk reduction of cancer.

Dr Valentine Macaulay and Dr Guillaume Rieunier have been awarded a 3-year CRUK Early Detection project grant (~£400k) to investigate the role of circulating insulin-like growth factor-1 (IGF-1) in cancer promotion and progression. High levels of circulating IGF-1 have been found to associate with increased risk of developing cancer. This association has been shown for several types of common cancer including cancers of the prostate, breast and colon.

The project will use cell line and in vivo models and clinical data, and will involve collaborators in the Departments of Oncology, Pathology, Surgery and Epidemiology. The research will aim to characterise mediators of high IGF-1 on cancer risk, to provide novel targets for screening and strategies for risk reduction. 

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.